These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 15786909

  • 1. [Anesthesia in hereditary peripheral muscular disease].
    Islander G, Jungner M.
    Lakartidningen; ; 102(8):566-71. PubMed ID: 15786909
    [No Abstract] [Full Text] [Related]

  • 2. Inhalation anesthetics and Duchenne's muscular dystrophy.
    Goresky GV, Cox RG.
    Can J Anaesth; 1999 Jun; 46(6):525-8. PubMed ID: 10391598
    [No Abstract] [Full Text] [Related]

  • 3. Volatile anesthetics and succinylcholine in cardiac ryanodine receptor defects.
    Swan H, Laitinen PJ, Toivonen L.
    Anesth Analg; 2004 Aug; 99(2):435-7, table of contents. PubMed ID: 15271719
    [Abstract] [Full Text] [Related]

  • 4. Malignant hyperthermia and muscular dystrophies.
    Gurnaney H, Brown A, Litman RS.
    Anesth Analg; 2009 Oct; 109(4):1043-8. PubMed ID: 19762730
    [Abstract] [Full Text] [Related]

  • 5. Duchenne muscular dystrophy: Which is the best anesthetic agent?
    Driessen J, Snoeck M.
    Paediatr Anaesth; 2008 Oct; 18(10):1007-8. PubMed ID: 18811853
    [No Abstract] [Full Text] [Related]

  • 6. [Malignant hyperthermia].
    Glahn KP.
    Ugeskr Laeger; 2003 Apr 21; 165(17):1763-8. PubMed ID: 12768904
    [Abstract] [Full Text] [Related]

  • 7. [Mild variant of malignant hyperthermia following succinylcholine and halogenated agent exposure].
    Fernández-García V, Bermejo MA, Vázquez C, Pereda MJ, Altarriba JM, Alvarez E.
    Rev Esp Anestesiol Reanim; 1995 Nov 21; 42(9):401-2. PubMed ID: 8584782
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Atypical malignant hyperthermia. A higher incidence than expected].
    Herrero E, Casinello F, de Stefano J, Fernández-Guisasola J, Pérez-Gallardo A.
    Rev Esp Anestesiol Reanim; 1996 Jan 21; 43(1):42-3. PubMed ID: 8851836
    [No Abstract] [Full Text] [Related]

  • 13. Malignant hyperthermia during desflurane-succinylcholine anesthesia for orthopedic surgery.
    Garrido S, Fraga M, Martín MJ, Belda J.
    Anesthesiology; 1999 Apr 21; 90(4):1208-9. PubMed ID: 10201695
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A protocol to manage malignant hyperthermia with general anesthesia.
    Roberts MW.
    Pediatr Dent; 1993 Apr 21; 15(1):45-6. PubMed ID: 7901841
    [No Abstract] [Full Text] [Related]

  • 18. Regarding: muscular dystrophy and the safety of inhalational agents.
    Schwartz D.
    Paediatr Anaesth; 2007 Jan 21; 17(1):96; author reply 96-7. PubMed ID: 17184451
    [No Abstract] [Full Text] [Related]

  • 19. [General anesthesia in a patient homozygous for the atypical variant of plasma pseudocholinesterase].
    Bermejo MA, Bujarrabal J, Torres V, Rodríguez-Vigil I, Mekhitharian A, Nespral B.
    Rev Esp Anestesiol Reanim; 1996 Jan 21; 43(6):224-5. PubMed ID: 8756241
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.